Table 2.
Comparison of the therapeutic effects and adverse events of neurogenic detrusor overactivity patients.
| NDO | BL | 1w | 4w | 12w | 4w vs. 12w |
|---|---|---|---|---|---|
| Patient number | 119 | 119 | 115 | 117 | |
| PVR (mL) | 187 ± 151 | 294 ± 183 * | 300 ± 194 * | 288 ± 181 * | 0.68 |
| PPBC | 3.4 ± 0.8 | - | 2.4 ± 0.8 * | 2.1 ± 1.0 * | 0.06 |
| NBSS-incontinence | 10.4 ± 7.0 | - | 7.0 ± 6.0 * | 6.0 ± 5.6 * | 0.04 |
| NBSS-voiding | 8.4 ± 4.8 | - | 6.1 ± 4.3 * | 5.6 ± 4.4 * | 0.19 |
| NBSS-consequence | 6.8 ± 2.8 | - | 5.0 ± 2.7 * | 4.5 ± 2.6 * | 0.11 |
| NBSS-QOL | 3.0 ± 0.9 | - | 2.3 ± 0.9 * | 2 ± 1 * | 0.06 |
| Symptomatic UTI (%) | 1 (0.8) | 5 (4.3) | 2 (1.7) | ||
| PVR > 350mL (%) | 12 (10.1) | 46 (38.7) | 54 (47.0) | 50 (42.7) | 0.6 |
| de novo AUR (%) | 2 (1.7) | 2 (1.7) | 1 (0.9) |
NDO: neurogenic detrusor overactivity; BL: baseline; w: week; PVR: postvoiding residual urine; NBSS: neurogenic bladder symptom score; QOL: quality of life; UTI: urinary tract infection; AUR: acute urinary retention; *: significantly different from baseline.